Lista de obras - Sophie Postel-Vinay - Dominio Público Uruguay

A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials

artículo científico publicado en 2016

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer

artículo científico publicado en 2013

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

artículo científico publicado en 2017

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

artículo científico publicado en 2009

Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials

artículo científico publicado en 2016

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

artículo científico publicado en 2015

Chromatin Regulators as a Guide for Cancer Treatment Choice

artículo científico publicado en 2016

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

artículo científico publicado en 2009

Clinical benefit of early phase clinical trial participation for advanced sarcoma patients

artículo científico publicado en 2010

Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise

scientific article published on 30 September 2019

Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma

artículo científico publicado en 2012

DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade

artículo científico publicado en 2018

ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform

artículo científico publicado en 2013

First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours

artículo científico publicado en 2017

How Much Can We Bet on Activity of BET Inhibitors Beyond NUT-Midline Carcinoma?

artículo científico publicado en 2019

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

artículo científico publicado en 2016

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

artículo científico publicado en 2016

In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?

artículo científico publicado en 2017

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

artículo científico publicado en 2016

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

artículo científico publicado en 2017

Modifying phase I methodology to facilitate enrolment of molecularly selected patients

artículo científico publicado en 2013

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

artículo científico publicado en 2016

Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials

artículo científico publicado en 2017

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer

article by Roman M Chabanon et al published 1 March 2019 in Journal of Clinical Investigation

Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience

artículo científico publicado en 2015

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

artículo científico publicado en 2016

Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape

artículo científico publicado en 2016

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

artículo científico publicado en 2017

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

artículo científico publicado en 2017

Rationale for anti-OX40 cancer immunotherapy

artículo científico publicado en 2015

Reovirus: Rationale and clinical trial update

artículo científico publicado en 2009

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

artículo científico publicado en 2009

Targeting FGFR Signaling in Cancer

artículo científico

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

artículo científico publicado en 2010

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

artículo científico publicado en 2012

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials

artículo científico publicado en 2014

Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?

artículo científico publicado en 2013

Lista de obras de Sophie Postel-Vinay

A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

Chromatin Regulators as a Guide for Cancer Treatment Choice

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

Clinical benefit of early phase clinical trial participation for advanced sarcoma patients

Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise

Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma

DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade

ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform

First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours

How Much Can We Bet on Activity of BET Inhibitors Beyond NUT-Midline Carcinoma?

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Modifying phase I methodology to facilitate enrolment of molecularly selected patients

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer

Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

Rationale for anti-OX40 cancer immunotherapy

Reovirus: Rationale and clinical trial update

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

Targeting FGFR Signaling in Cancer

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials

Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?